Cancer test producer loses DNA patent

摘要

A US medical diagnostic company who produce genetic tests has had the right to patent DNA sequences used for detecting breast and ovarian cancers overturned. Myriad Genetics — who patented the sequences to protect its genetic testing — will appeal the court ruling in which New York District Judge Robert Sweet said the breast cancer genes B and BRCA2 are 'laws of nature' and can't be patented. Myriad Genetics exclusive patents meant they were the only US company licensed to sequence the genes.